B. Riley raised the firm’s price target on Capricor Therapeutics (CAPR) to $50 from $21 and keeps a Buy rating on the shares. The clinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback